Correction: Survival outcomes of real world patients with metastatic hormone-sensitive prostate cancer who do not achieve optimal PSA response with intensified androgen deprivation therapy with docetaxel or androgen receptor pathway inhibitors

Affiliations

¹ Division of Medical Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.
² Division of Medical Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA. neeraj.agarwal@hci.utah.edu.

^# Contributed equally.

Published Erratum

Georges Gebrael et al. Prostate Cancer Prostatic Dis. 2024 Jun.

. 2024 Jun;27(2):357.

doi: 10.1038/s41391-023-00706-x.

¹ Division of Medical Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.
² Division of Medical Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA. neeraj.agarwal@hci.utah.edu.

^# Contributed equally.

No abstract available

Erratum for

Survival outcomes of real world patients with metastatic hormone-sensitive prostate cancer who do not achieve optimal PSA response with intensified androgen deprivation therapy with docetaxel or androgen receptor pathway inhibitors.
Gebrael G, Sayegh N, Thomas VM, Chigarira B, Tripathi N, Jo YJ, Li H, Sahu KK, Srivastava A, McFarland T, Maughan BL, Swami U, Agarwal N. Gebrael G, et al. Prostate Cancer Prostatic Dis. 2024 Jun;27(2):279-282. doi: 10.1038/s41391-023-00696-w. Epub 2023 Jul 17. Prostate Cancer Prostatic Dis. 2024. PMID: 37460732